Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells

Journal of Cell Communication and Signaling

Volumn 6, Issue 2, 2012, Pages 87-95

  Walsh, Logan A ^a   Cepeda, Mario A ^a   Damjanovski, Sashko ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Breast cancer; MCF 7; MDA MB 231; MMP proteolysis; T47D; TIMP

Indexed keywords

PLASMID DNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CELL STRAIN MCF 7; CELL VIABILITY; DNA VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL CULTURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; ZYMOGRAPHY;

EID: 84863106677     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-011-0157-8     Document Type: Article

References (33)

1. Abdallah MA, Abdullah HI, Kang S, Taylor DD, Nakajima ST, Gercel-Taylor C (2007) Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study. Fertil Steril 87:978-981 (Pubitemid 46566357)
2. Alakus H, Grass G, Hennecken JK, Bollschweiler E, Schulte C, Drebber U, Baldus SE, Metzger R, Hölscher AH, Mönig SP (2008) Clinico-pathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 23:917-923
3. Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe MJ, Huet G (2000) Specific expression of matrix metal-loproteinases 1,3,9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18:171-178 (Pubitemid 32165251)
4. Bartsch JE, Staren ED, Appert HE (2003) Matrix metalloproteinase expression in breast cancer. J Surg Res 110:383-392 (Pubitemid 36683036)
5. Dove A (2002) MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med 8:95 (Pubitemid 34155108)
6. Ehrenfeld P, Conejeros I, Pavicic MF, Matus CE, Gonzalez CB, Quest AF, Bhoola KD, Poblete MT, Burgos RA, Figueroa CD (2011) Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and - insensitive breast cancer cells. Cancer Lett 301:106-118
7. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC (2009) Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9:20
8. Gill SE, Kassim SY, Birkland TP, Parks WC (2010) Mouse models of MMP and TIMP function. Methods Mol Biol 622:31-52
9. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11:R24
10. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ (2006) Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 46:1199-1209 (Pubitemid 44139495)
11. Jones JL, Shaw JA, Pringle JH, Walker RA (2003) Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol 201:562-572 (Pubitemid 38256405)
12. Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, Werb Z, Baker A, Libert C, Krell HW, Foidart JM, Noël A, Rakic JM (2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17:2290-2302
13. Lambert E, Dasse E, Haye B, Petitfrere E (2004) TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49:187-198 (Pubitemid 38251351)
14. Larsen MB, Stephens RW, Brunner N, Nielsen HJ, Engelholm LH, Christensen IJ, Stetler-Stevenson WG, Hoyer-Hansen G (2005) Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients. Scand J Immunol 61:449-460 (Pubitemid 40695016)
15. Lauber SN, Gooderham NJ (2011) The cooked meat-derived mammary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine promotes invasive behaviour of breast cancer cells. Toxicology 279:139-145
16. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558-564 (Pubitemid 39201241)
17. Noda M, Takahashi C (2007) Recklessness as a hallmark of aggressive cancer. Cancer Sci 98:1659-1665 (Pubitemid 47487898)
18. Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M, Stetler-Stevenson WG (2004) Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 64:9062-9069 (Pubitemid 39665518)
19. Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26:587-956
20. Ratnikov BI, Deryugina EI, Strongin AY (2002) Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest 82(11):1583-90 (Pubitemid 35332917)
21. Rhee JS, Coussens LM (2002) RECKing MMP function: implications for cancer development. Trends Cell Biol 12:209-211 (Pubitemid 34327606)
22. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG (2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114:171-180 (Pubitemid 36936911)
23. Stetler-Stevenson WG (2008) The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev 27:57-66
24. Stetler-Stevenson WG, Seo DW (2005) TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11:97-103 (Pubitemid 40348986)
25. Svagzdys S, Lesauskaite V, Pangonyte D, Saladzinskas Z, Tamelis A, Pavalkis D (2011) Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma. Tohoku J Exp Med 223:67-73
26. Toth M, Fridman R (2001) Assessment of gelatinases (MMP-2 and MMP-9 by gelatin zymography. Methods Mol Med 57:163-174
27. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Nature 415:530-536
28. Walsh LA, Carere DA, Cooper CA, Damjanovski S (2007) Membrane type-1 matrix metalloproteinases and tissue inhibitor of metalloproteinases-2 RNA levels mimic each other during Xenopus laevis metamorphosis. PLoS One 2:e1000
29. Walsh LA, Damjanovski S (2011) IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition. Cell Commun Signal 9:10
30. Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, Chung V, Corcoran ML, Kleiner DE, Stetler-Stevenson WG (1999) Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli, Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J Biol Chem 274:21362-21368
31. Yana I, Seiki M (2002) MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 19:209-215 (Pubitemid 34555419)
32. Zhang A, Meng L, Wang Q, Xi L, Chen G, Wang S, Zhou J, Lu Y, Ma D (2006) Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep 15:831-836
33. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJ, Cao J (1998) Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 273:1216-1222 (Pubitemid 28049224)